Franklin Resources Inc. Has $1.87 Million Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Franklin Resources Inc. lessened its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 58.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 154,367 shares of the company’s stock after selling 217,863 shares during the quarter. Franklin Resources Inc.’s holdings in Elanco Animal Health were worth $1,869,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Orion Portfolio Solutions LLC raised its holdings in Elanco Animal Health by 14.3% during the 4th quarter. Orion Portfolio Solutions LLC now owns 33,396 shares of the company’s stock worth $404,000 after purchasing an additional 4,169 shares during the last quarter. Norges Bank acquired a new stake in shares of Elanco Animal Health during the 4th quarter worth approximately $47,424,000. Blair William & Co. IL raised its stake in shares of Elanco Animal Health by 17.3% during the fourth quarter. Blair William & Co. IL now owns 70,430 shares of the company’s stock worth $853,000 after buying an additional 10,400 shares during the last quarter. WINTON GROUP Ltd acquired a new position in Elanco Animal Health in the fourth quarter valued at approximately $141,000. Finally, Prudential Financial Inc. boosted its position in shares of Elanco Animal Health by 40.4% in the 4th quarter. Prudential Financial Inc. now owns 4,224,997 shares of the company’s stock worth $51,165,000 after purchasing an additional 1,214,992 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

NYSE ELAN opened at $8.64 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The stock has a market cap of $4.29 billion, a price-to-earnings ratio of 21.60, a PEG ratio of 2.50 and a beta of 1.44. The business has a 50 day simple moving average of $10.59 and a 200 day simple moving average of $12.02. Elanco Animal Health Incorporated has a 52-week low of $8.03 and a 52-week high of $18.80.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company’s revenue was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.08 earnings per share. Analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the business’s stock in a transaction dated Tuesday, March 11th. The shares were acquired at an average price of $10.20 per share, with a total value of $102,000.00. Following the completion of the transaction, the director now directly owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.57% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ELAN. Morgan Stanley dropped their price objective on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus lowered their price target on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Barclays reduced their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. UBS Group lowered their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Finally, Piper Sandler reduced their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $15.17.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.